4 years ago

Response to ‘Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after PD1 inhibition with nivolumab’

Justin P. Bandino, Dirk M. Elston
We thank Dr. Fung and colleagues for their interest in our publication concerning eruptive keratoacanthomas (KAs) and bullous pemphigoid-like disease in patients on anti-programmed cell death-1 (PD-1) immunotherapy.1 We agree that nivolumab, like pembrolizumab, seems to share the same immune-related adverse event profile, and in fact our second case occurred in a patient on nivolumab (after no visible reduction in metastatic disease on pembrolizumab). This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jdv.14510

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.